🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for MALT Lymphoma

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia NCT05281809Phase 21 site📍 Pittsburgh John Lister · Tests: Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous) Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE) NCT06534463n/a1 site📍 Shanghai Ruijin Hospital · Tests: All treatment regimen selections and usage will be determined by the physician based on clinical practice and/or the re… This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma NCT07121946Phase 16 sites📍 Duarte📍 St Louis📍 Buffalo LTZ Therapeutics, Inc. · Tests: LTZ-301, LTZ-301, LTZ-301 Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma NCT07763210Phase 21 site📍 Nashville Vanderbilt-Ingram Cancer Center · Tests: Therapeutic Hydrocortisone, Cytarabine, Dexamethasone, Methylprednisolone, Cyclophosphamide A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma NCT06563505Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Mosunetuzumab, Zanubrutinib SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265Phase 15 sites📍 Denver📍 Atlanta📍 Fairway Verismo Therapeutics · Tests: SynKIR-310 Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma NCT04792502Phase 23 sites📍 New Haven📍 New Brunswick📍 Providence Brown University · Tests: Mosunetuzumab, Lenalidomide Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas NCT04883437Phase 21 site📍 Atlanta Emory University · Tests: Acalabrutinib, Obinutuzumab, Quality-of-Life Assessment, Questionnaire Administration Allo HSCT Using RIC and PTCy for Hematological Diseases NCT05805605Phase 21 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine, Cyclophosphamide, Bone Marrow Cell Transplant Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma NCT06566807Phase 21 site📍 Huai'an Huai'an First People's Hospital · Tests: Orelabrutinib, obinutuzumab Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas NCT06513234Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: Orelabrutinib and obinutuzumab Cohort Study for Gastric MALT Lymphoma NCT06454149n/a3 sites📍 Ansan-si📍 Seongnam-si📍 Seoul Seoul National University Hospital · Tests: MALT lymphoma Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL) NCT00923507n/a1 site📍 Bethesda National Heart, Lung, and Blood Institute (NHLBI) Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma NCT06442475Phase 21 site📍 Seattle University of Washington · Tests: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Mosunetuzumab, Positron Emission Tomography CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma NCT06026319Phase 11 site📍 Boston Marcela V. Maus, M.D.,Ph.D. · Tests: CD79b-19 CAR T cells, Cyclophosphamide, Fludarabine Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader NCT05294731Phase 1, Phase 229 sites📍 Bengbu📍 Hefei📍 Beijing BeOne Medicines · Tests: Tacabrutideg Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL NCT07441993Phase 214 sites📍 Guangzhou📍 Zhengzhou📍 Wuhan Institute of Hematology & Blood Diseases Hospital, China · Tests: Orelabrutinib Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. NCT04223765Phase 11 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: CAR.k.28, Fludarabine, Cyclophosphamide, Bendamustine Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT Lymphoma NCT07554898Phase 22 sites📍 Hangzhou📍 Hangzhou Zhejiang Cancer Hospital · Tests: Orelabrutinib, Ultra-low-dose Radiation Therapy Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma. NCT06454968Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: Orelabrutinib, obinutuzumab, lenalidomide Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL) NCT06504940Phase 21 site📍 Hangzhou First Affiliated Hospital of Zhejiang University · Tests: Orelabrutinib combined with bendamustine and rituximab, Orelabrutinib combined with obinutuzumab Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma NCT05700149n/a50 sites📍 Miami📍 Rochester📍 New York International Extranodal Lymphoma Study Group (IELSG) Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study NCT06151730n/a1 site📍 Rochester Mayo Clinic · Tests: Non-Interventional Study A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma NCT05929612Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Ultra Low Dose 4 Gy Radiation Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL NCT07208981Phase 21 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Orelabrutinib, Zebetuzumab, Lenalidomide, Bendamustine + Rituximab Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma NCT06859008Phase 11 site📍 Duarte City of Hope Medical Center · Tests: Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography A Study of APG-3288 in Relapsed/Refractory Blood Cancers NCT07424833Phase 16 sites📍 Los Angeles📍 Jacksonville📍 Grand Rapids Ascentage Pharma Group Inc. · Tests: APG-3288 Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma NCT07583810Phase 21 site📍 Duarte City of Hope Medical Center · Tests: Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging Preliminary Assessment of [18F]BL40 in PET/CT Scans NCT06224309n/a1 site📍 Vancouver British Columbia Cancer Agency · Tests: 18F-BL40 PET/CT, 18F-FDG PET/CT, Routine Blood Draw - Phase 1 only A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies NCT04830137Phase 116 sites📍 Duarte📍 Orange📍 San Francisco Nurix Therapeutics, Inc. · Tests: NX-2127
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy